Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_4
1
17%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(5)

Detailed Status

Completed5
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

completed583%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_2

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
recruitingphase_4

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

NCT06441955
completed

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

NCT05765578
completed

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

NCT06006858
completedphase_3

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04761822Phase 2

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

Completed
NCT06441955Phase 4

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Recruiting
NCT05765578

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

Completed
NCT06006858

Post Authorization Safety Study Moderna COVID-19 Primary Vaccine

Completed
NCT04811664Phase 3

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

Completed
NCT04806113Phase 3

COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6